Disclosures: Naoto Kawabe: Nothing to Disclose, Teiji Kuzuya: Chugai Pharmaceutical Co: Speaking and Teaching, Eisai: Speaking and Teaching, Eli Lilly Japan: Speaking and Teaching, AstraZeneca: Speaking and Teaching, Yoshiki Hirooka: Nothing to Disclose 2614 SAFETY AND EFFICACY OF NAFAMOSTAT MESYLATE ANTICOAGULATION IN CENTRIFUGAL ARTIFICIAL LIVER SUPPORT SYSTEM FOR ALF AND ACLF PATIENTS AT HIGH RISK OF BLEEDING Zhu Xinfang 1 Bing-Yao Wang 1 Jian-Ming Zheng 1 Rong Xia 1 , 1 Huashan Hospital, Fudan University Background: Patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are consistently at high risk of bleeding and most exhibit decreased platelet levels, presenting a challenge for the conventional approach to artificial liver support systems (ALSS)

The highly selective permeability of the BBB largely depends on the presence of continuous TJs that connect ECs, and so it follows that dysregulation of the expression of TJ proteins, such as occludin, claudin-5 and ZO-1, can critically influence BBB permeability
Genetic analysis of potential biomarkers and therapeutic targets in ferroptosis from psoriasis
In summary, AI technologies, including machine learning, deep learning, and natural language processingoffer powerful solutions to combat antifungal resistance